Patients at risk of complications of Staphylococcus aureus bloodstream infection.

Détails

Ressource 1Télécharger: REF.pdf (302.65 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_F2C1CC892374
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Patients at risk of complications of Staphylococcus aureus bloodstream infection.
Périodique
Clinical Infectious Diseases
Auteur⸱e⸱s
del Rio A., Cervera C., Moreno A., Moreillon P., Miró J.M.
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Statut éditorial
Publié
Date de publication
2009
Volume
48 Suppl 4
Pages
S246-S253
Langue
anglais
Résumé
Staphylococcus aureus is one of the most common causative pathogens of bloodstream infections (BSIs). In approximately one-half of patients with S. aureus BSI, no portal of entry can be documented. This group of patients has a high risk of developing septic metastases. Similarly, patient populations at high risk of S. aureus BSI and BSI-associated complications include patients receiving hemodialysis, injection drug users, patients with diabetes, and patients with preexisting cardiac conditions or other comorbidities. One of the most severe complications of S. aureus BSI is infective endocarditis, and S. aureus is now the most common cause of infective endocarditis in the developed world. Patients with methicillin-resistant S. aureus BSI or infective endocarditis have higher rates of mortality, compared with patients with methicillin-susceptible S. aureus infection. Nasal carriage is the most important source of S. aureus BSI. Better eradication and control strategies, including nasal decolonization and more-active antibiotics, are needed to combat S. aureus BSIs.
Mots-clé
Bacteremia/complications, Bacteremia/drug therapy, Carrier State, Endocarditis/etiology, Humans, Methicillin-Resistant Staphylococcus aureus/isolation & purification, Nasal Cavity/microbiology, Risk Factors, Staphylococcal Infections/complications, Staphylococcal Infections/drug therapy, Staphylococcus aureus/isolation & purification
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/02/2010 17:48
Dernière modification de la notice
14/02/2022 8:57
Données d'usage